Summary

Overview
Global Pouchitis Market reached US$ XX Billion in 2022 and is expected to reach US$ XX Billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
The global pouchitis market has been experiencing significant growth over the years owing to the increasing prevalence of gastrointestinal diseases and the increase in the surgical procedures of IBD drive market growth. After a patient has had a total proctocolectomy (removal by colon and rectum surgery), an ileal pouch-anal anastomosis (IPAA) is performed, which leads to pouchitis.
Moreover, the increase in product launches and approvals drives the market’s growth. The antibiotics segment is dominant in the market share and acts as the first line of medication. The use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially over a long period of time, will develop pouchitis. Alternative antibiotic availability will aid in market growth.
The antibiotics segment accounts for over half of the market share. Similarly, North America dominates the market share by launching and introducing novel products and treatment procedures. The healthcare infrastructure and the improved healthcare in this region hold the region in the dominant position.
Dynamics
Prevalence of Inflammatory Bowel Disease is expected to Drive the Market Growth
The prevalence of bowel inflammatory disease is driving the growth of the market. For instance, according to CDC, n estimated 3.1 million adults (1.3%) in the United States have been diagnosed with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It is a broad term that indicates chronic inflammation of the gastrointestinal tract. IBD has been associated with poor quality of life and extensive morbidity and often results in complications requiring hospitalizations and surgical procedures.
Pouchitis can frequently develop in patients with IBD after creating an IPAA, significantly impairing quality of life. Additionally, according to NIH, About 10% of patients with IBD who develop pouchitis require pouch excision, and several risk factors of the failure have been reported.
Increase in Ileal Pouch- Anal Anastomosis (IPAA) will Drive the Market Growth
The increase in IPAA surgeries will elevate the market growth. IPAA is preferred for ulcerative colitis. For instance, according to Crohn’s and Colitis Foundation, approximately 30% of ulcerative colitis patients require surgery during their disease course. According to NIH, the prevalence of ulcerative colitis is estimated to be 156 to 291 cases per 100,000 persons per year. The preferred and most common surgery is the staged total proctocolectomy with ileal pouch-anal anastomosis (IPAA).
Despite the benefits of intestinal continuity and improved quality of life, IPAA is associated with multiple complications, the most common of which is pouchitis. The total proctocolectomy with ileal pouch–anal anastomosis (IPAA) is the surgical intervention of choice in subjects affected by ulcerative colitis (UC). Thus, the increase in IPAA surgeries is expected to raise market growth.
Side Effects of the Available Treatment Options can Impede the Market Growth
The side effects of the available treatment options can decline the market growth. The long-term use of antibiotics is ineffective in achieving clinical remission, where treatment is no longer needed to control symptoms. Long-term use of antibiotics for chronic pouchitis is associated with antibiotic-related side effects and the development of antibiotic resistance.
Side effects of antibiotics, development of resistance to antibiotics, and the development of Clostridium. Additionally, Side effects included vomiting, dysgeusia (metallic taste in mouth), or transient peripheral neuropathy (damage to nerves). The symptoms persist despite a course of more than four weeks of antibiotic therapy. Thus, the side effects of the treatment will decline the market growth.
Segment Analysis
The global pouchitis market is segmented based on type, treatment, distribution channel and region.
Antibiotics Segment is Expected to hold a Dominant Position in the Market Share
Antibiotics are first-line therapy for acute pouchitis, consisting of an oral antibiotic for two weeks. Pouchitis, often developing after colectomy and ileal pouch-anal anastomosis for ulcerative colitis, is highly responsive to antibiotics. Ciprofloxacin and/or metronidazole are commonly used, often for prolonged periods.
Patients with acute pouchitis are commonly treated with antibiotics, specifically ciprofloxacin and/or metronidazole, for an empiric 2-week course. Many patients may become antibiotic-dependent, and some require long antibiotic courses. Most patients with acute pouchitis have symptomatic improvement (e.g., improved stool frequency, no urgency) within three days of antibiotic therapy. The benefits of antibiotics against pouchitis disease make the antibiotics preferable. Thus, the above factors will drive the segment growth.
Geographical Penetration
North America Holds a Significant Position in the Market Share
Increase in the number of product approvals and launches due to the presence of major key players in the region and the improved healthcare system in the region is expected to hold a significant position in the market share. For instance, on November 10, 2022, the Food and Drug Administration (FDA) granted Orphan Drug designation to AMT-101 for treating pouchitis, an inflammation that develops following ileal pouch-anal anastomosis surgery in patients with ulcerative colitis.
Additionally, on December 17, 2021, Takeda Pharmaceutical Company Limited (“Takeda”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended the approval of intravenous (IV) vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) and have had an inadequate response with or lost response to antibiotic therapy. Thus, the launches and approvals by the companies will drive market growth over the forecast period.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical markets worldwide, including the global pouchitis market. The supply chains were disrupted due to the lockdowns. The manufacturing processes of the products were interrupted as the companies faced the crisis.
The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions that delayed the diagnosis, treatment procedures, and follow-up checking with the healthcare professional. The prognosis of the disease has experienced severity due to the lack of availability of the medicine.
The COVID-19 pandemic severely disrupted the growth of the markets. The companies experienced unprecedented losses worldwide. The restriction in the supply of non-essential medicine has created a drug crisis. The company’s focus has shifted to manufacturing emergency medicine for COVID-19, which was killing a number of people. However, the guidelines and the restrictions aided in stopping the spread of the virus. Thus, COVID-19 have impacted the market.
By Type
• Acute Pouchitis
• Relapsing Pouchitis
• Chronic Pouchitis
By Treatment
• Antibiotics
• Probiotics
• Antidiarrheal Agents
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On March 30, 2023, Takeda confirmed that the New England Journal of Medicine (NEJM) had published positive data from the Phase 4 EARNEST study of vedolizumab to treat chronic pouchitis.
• On February 3, 2023, Takeda announced that the European Commission had granted marketing authorization for the intravenous (IV) formulation of vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) and have had an inadequate response with or lost response to antibiotic therapy. Vedolizumab is the first treatment indicated for active chronic pouchitis across the European Union.
Competitive Landscape
The major global players in the market include Dr. Reddy's Laboratories, Ravoos Laboratories Ltd., Pfizer, Wellona Pharma, Aden Healthcare, Manus Aktteva Biopharma LLP, Anant Pharmaceuticals Pvt Ltd, Enomark Pharma, Reliance Life Sciences, Atom Pharma among others.
Why Purchase the Report?
• To visualize the global pouchitis market segmentation based on type, treatment, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pouchitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global pouchitis market report would provide approximately 61 tables, 58 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Prevalence of inflammatory bowel disease (IBD)
4.1.1.2. Increase in ileal pouch-anal anastomosis (IPAA)
4.1.2. Restraints
4.1.2.1. Side effects of the available treatment options
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Portland*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Blended
7.4. Others
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Antibiotics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Probiotics
8.4. Antidiarrheal Agents
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Dr. Reddy's Laboratories*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Ravoos Laboratories Ltd.
12.3. Pfizer
12.4. Wellona Pharma
12.5. Aden Healthcare
12.6. Manus Aktteva Biopharma LLP
12.7. Anant Pharmaceuticals Pvt Ltd
12.8. Enomark Pharma
12.9. Reliance Life Sciences
12.10. Atom Pharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us